Predicted protein targets (top 19)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GSK3B | P49841 | 2/20 | 0.61 |
| ▸ | GRM5 | P41594 | 1/20 | 0.48 |
| ▸ | CLK1 | P49759 | 1/20 | 0.46 |
| ▸ | DYRK1A | Q13627 | 1/20 | 0.46 |
| ▸ | DYRK1B | Q9Y463 | 1/20 | 0.46 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.46 |
| ▸ | P4HB | P07237 | 3/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.45 |
| ▸ | MAPT | P10636 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | S1PR3 | Q99500 | 1/20 | 0.45 |
| ▸ | VNN1 | O95497 | 3/20 | 0.44 |
| ▸ | IRAK4 | Q9NWZ3 | 1/20 | 0.44 |
| ▸ | KAT6A | Q92794 | 1/20 | 0.43 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.43 |
| ▸ | ELANE | P08246 | 1/20 | 0.43 |
| ▸ | XDH | P47989 | 1/20 | 0.42 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4083136 | 0.83 | GSK3B (0.58) | GSK3BGRM5CLK1DYRK1ADYRK1B | |
| SCHEMBL2164429 | 0.82 | GSK3B (0.62) | GSK3BGRM5CLK1DYRK1ADYRK1B | |
| SCHEMBL60691 | 0.82 | GSK3B (0.62) | GSK3BGRM5XDHSLC22A12 | |
| SCHEMBL29441888 | 0.82 | GSK3B (0.62) | GSK3BGRM5XDHSLC22A12 | |
| SCHEMBL1679846 | 0.82 | GSK3B (0.41) | GSK3BGRM5 | |
| SCHEMBL23079142 | 0.80 | GSK3B (0.61) | GSK3BGRM5CLK1DYRK1ADYRK1B | |
| SCHEMBL2041048 | 0.80 | GSK3B (0.61) | GSK3BGRM5CLK1DYRK1ADYRK1B | |
| SCHEMBL39137 | 0.80 | GSK3B (0.61) | GSK3BGRM5CLK1DYRK1ADYRK1B | |
| SCHEMBL11706688 | 0.80 | GSK3B (0.61) | GSK3BGRM5XDHSLC22A12 | |
| SCHEMBL11673528 | 0.80 | GSK3B (0.66) | GSK3BGRM5CLK1DYRK1ADYRK1B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090036449-A1 | Indazolesquaric Acid Derivatives as Chk1, Chk2 and Sgk Inhibitors | MERCK PATENT GMBH (DE) | 2009-02-05 | — | — | US | disclosed |
| EP-1866288-A1 | INDAZOLE SQUARIC ACID DERIVATIVES AS CHK1-, CHK2- AND SGK- INHIBITORS | Merck Patent GmbH (DE) | 2007-12-19 | — | — | EP | disclosed |
| WO-2006105865-A1 | INDAZOLE SQUARIC ACID DERIVATIVES AS CHK1-, CHK2- AND SGK- INHIBITORS | MERCK PATENT GMBH (DE) | 2006-10-12 | — | — | WO | disclosed |
| US-5332811-A | Antitumor intermediates | THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL (US) | 1994-07-26 | — | — | US | disclosed |
| EP-0014567-B1 | PROCESSES FOR PREPARATION OF BETA-LACTAM COMPOUNDS | ELI LILLY AND COMPANY (US) | 1984-01-18 | — | — | EP | disclosed |
| US-4271305-A | ANTIBIOTICS | ELI LILLY AND COMPANY (US) | 1981-06-02 | — | — | US | disclosed |
| US-4226986-A | 7-ACYLAMINO-3-HYDROXY-3-CEPHEM COMPOUND, TRIARYL PHOSPHITE DIHALIDE | ELI LILLY AND COMPANY (US) | 1980-10-07 | — | — | US | disclosed |
| US-4223133-A | USING A TRIARYL PHOSPHITE-HALOGEN COMPLEX | ELI LILLY AND COMPANY (US) | 1980-09-16 | — | — | US | disclosed |
| EP-0014567-A1 | Processes for preparation of beta-lactam compounds | ELI LILLY AND COMPANY (US) | 1980-08-20 | — | — | EP | disclosed |
| US-4211702-A | TRIARYLPHOSPHITE-HALOGEN COMPLEX HALOGENATING AGENT | ELI LILLY AND COMPANY (US) | 1980-07-08 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090036449-A1 | Indazolesquaric Acid Derivatives as Chk1, Chk2 and Sgk Inhibitors | CHEK2, CHEK1, SIK2 | GSK3B 311/4885GRM5 3280/4885CLK1 38/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.